![]() There will be 1 additional year of follow-up for a total of 4 years after the first year of treatment with a trastuzumab-based therapy. They will subsequently receive 5 boosters over the next 2.5 years, equating to total of 11 injections over 3 years of treatment. Participants will receive 6 intradermal injections of GLSI-100 or saline placebo for the primary immunization series over the first 6 months. After treatment with the trastuzumab-based therapy has come to completion, HLA-A*02–positive patients will be randomized to GLSI-100 or saline placebo. Patients with stage IV disease will be excluded.įirst, patients will undergo a screening period and within 3 months prior to the end of their trastuzumab-based treatment, they will be screened for HLA type. With the prospective, randomized, double-blinded, multicenter FLAMINGO-01 trial, investigators seek to reproduce the phase 2b trial and further explore the use of GLSI-100 in HER2/neu- and HLA-A*02–positive patients, following surgery and the first year of treatment with any trastuzumab-based therapy or an approved biosimilar.Īdditional major screening criteria include having residual disease following neoadjuvant therapy and surgery, and pathologic complete response (pCR) if the patient has stage IIII disease at the time of presentation. GP2 was also found to induce a strong immune response per local skin tests and immunological assays. Previously, results from a prespecified subgroup analysis of a prospective, randomized, single-blinded, placebo-controlled, multicenter phase 2b trial showed that after a median 5 years of follow-up, no recurrences were observed in the HER2/neu-positive adjuvant setting if the HLA-A*02–positive patient was given the 6 primary intradermal GP2 injections over the first 6 months ( P =. The study has also been granted approval from the Central Institutional Review Board. Moreover, the third clinical lot of the product using a commercial line has been manufactured, and commercial lots of the GP2 active ingredient has been contracted so that the biologics license application can be filed.Īdditionally, the central laboratory has been contracted to screen for HLA type, and drug and biological sample storage sites, along with other trial infrastructure, has also been put into place. Greenwich LifeSciences, Inc., the developer of GP2, has announced that a contract research organization has been contracted for the start-up of the trial, along with project and data management and clinical data monitoring. GP2 is a biologic 9 amino acid peptide of the HER2/neu protein the agent will be delivered in combination with the FDA-approved GM-CSF, which will serve to stimulate an immune response and target HER2/neu-expressing cancers. ![]() Significant progress has been made toward the initiation of the phase 3 FLAMINGO-01 trial, which will evaluate the combination of the immunotherapy GP2 with granulocyte macrophage colony stimulating factor (GM-CSF GLSI-100) in the adjuvant treatment of HER2/neu- and HLA-A*02–positive patients following surgery and trastuzumab (Herceptin)-based therapy.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |